MLYS - NASDAQ
Mineralys Therapeutics, Inc.
$25.06
-19%Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
At a Glance
Live SnapshotMineralys Therapeutics, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Steady FCF growth indicates consistent cash generation improvement. On a positive trajectory.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Mineralys Therapeutics, Inc. Cash Flow Statement
MLYS • NASDAQ
| Mineralys Therapeutics, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||
-154.7M | -177.8M | -71.9M | -29.8M | -19.4M | -3.4M | |
59K | 43K | 0.0 | 0.0 | 0.0 | 0.0 | |
19.3M | 11.3M | 5.1M | 455K | 80K | 1K | |
-9.9M | -9.4M | -6.9M | -649K | 684K | 482K | |
2.7M | 9.5M | -7.5M | 772K | 4.1M | 480K | |
-142.4M | -166.3M | -81.2M | -29.2M | -14.6M | -2.5M | |
INVESTING ACTIVITIES | ||||||
-15K | -96K | (0.0) | (0.0) | (0.0) | (0.0) | |
-814.7M | -373.4M | -348M | -71.8M | (0.0) | (0.0) | |
425M | 488.5M | 187.5M | 50M | 0.0 | 0.0 | |
-389.8M | (115M) | -160.5M | -21.8M | (0.0) | (0.0) | |
FINANCING ACTIVITIES | ||||||
591M | 116.1M | 203M | -1.6M | 0.0 | -20K | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 3.9M | |
(0.0) | (0.0) | (0.0) | -1.6M | (0.0) | (0.0) | |
0.0 | 83K | 258K | 0.0 | 0.0 | 0.0 | |
591M | 116.1M | 203.2M | 128M | 23.8M | 3.8M | |
CASH FLOW SUMMARY | ||||||
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 42K | |
58.8M | 64.8M | -38.4M | 77M | 9.3M | 1.4M | |
114.1M | 49.3M | 87.7M | 10.7M | 1.4M | 0.0 | |
172.9M | 114.1M | 49.3M | 87.7M | 10.7M | 1.4M | |
-142.4M | -166.4M | -81.2M | -29.2M | -14.6M | -2.5M |
SEC Filings
MLYS - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | June 03, 2026 | June 02, 2026 | 2026 | |
8-K 8-K 2026 N/A | June 03, 2026 | June 03, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 22, 2026 | May 21, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 06, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 06, 2026 | May 06, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 08, 2026 | May 21, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 12, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 12, 2026 | March 12, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 09, 2026 | March 06, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 06, 2026 | January 06, 2026 | 2026 |
Related Guides
Continue your MLYS research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.